Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Zhaoke Ophthalmology Ltd. ( (HK:6622) ).
Zhaoke Ophthalmology Limited has entered into three distribution agreements with Interpharma to commercialize NVK002, BRIMOCHOL™ PF, and six glaucoma drugs in Thailand. These agreements grant Interpharma exclusive rights to import, distribute, and sell these products, potentially enhancing Zhaoke’s market presence in Southeast Asia and expanding access to innovative ophthalmic treatments.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, providing innovative treatments and generic drugs for eye conditions. Their primary products include NVK002 for myopia progression control, BRIMOCHOL™ PF for presbyopia, and several drugs targeting glaucoma.
YTD Price Performance: 28.33%
Average Trading Volume: 2,643,883
Technical Sentiment Signal: Buy
Current Market Cap: HK$852M
For detailed information about 6622 stock, go to TipRanks’ Stock Analysis page.